inhibitor

Treatment with the new KRAS inhibitor begins in the phase 1/1B study, COVALENT-10

Leave a Comment / Novel / By

The COVALENT-102 study initiated BMF-219 treatment in patients with KRAS-mutated, advanced solid tumors. The first patient with KRAS– mutated, inoperable, locally advanced or metastatic solid tumor was dosed with BMF-219, signaling the start of treatment in the phase 1/1b study COVALENT-102 (NCT05631574).1 BMF-219 is a pan-KRAS targeting inhibitor KRAS G12C, G12D, G12R and others KRAS …

Treatment with the new KRAS inhibitor begins in the phase 1/1B study, COVALENT-10 Read More »

BenevolentAI Submits CTA for BEN-8744, Oral PDE10 Inhibitor, as First-in-Class Treatment for Ulcerative Colitis

Leave a Comment / Novel / By

BEN-8744 demonstrates the potential of the Benevolent Platform™️ to discover new targets not previously associated with a particular disease The start of Phase I of the clinical trial is planned for the first half of 2023 LONDON, December 21, 2022—(BUSINESS WIRE)–BenevolentAI ​​(Euronext Amsterdam: BAI), a leading AI-powered clinical-stage drug discovery company, announces that it has …

BenevolentAI Submits CTA for BEN-8744, Oral PDE10 Inhibitor, as First-in-Class Treatment for Ulcerative Colitis Read More »

When combined, the new inhibitor and existing therapy enhance each other’s anti-cancer effects MUSC

Leave a Comment / Novel / By

A research team at the Medical University of South Carolina (MUSC) has developed new compounds that show early promise in the fight against the rare pediatric cancer neuroblastoma when paired with the existing cancer drug bortezomib (Velcade, Takeda Oncology). The new compounds block or inhibit an enzyme known as lysine-specific demethylase 1 (LSD1). The MUSC …

When combined, the new inhibitor and existing therapy enhance each other’s anti-cancer effects MUSC Read More »